Reports

Turquoise's public comment on CMS-0042-NC

Turquoise Health's public comment on CMS-0042-NC supporting binding upfront cost estimates and providing detailed feedback on PC-12 and TD-19 regarding price transparency implementation and good faith estimate frameworks. Read our full analysis.

Is price transparency helping?

Turquoise Health analyzed commercially negotiated rates at 200+ hospitals across the 10 largest US metros finding significant price convergence, with high rates declining 6.3% annually and low rates rising 3.4% annually. Is price transparency helping? The data says yes. Explore the data.

Turquoise's public comment on CMS-1786-P

Turquoise Health is in full support of CMS' commitment to continued improvement and iteration of hospital price transparency requirements. The proposed requirements would increase efficacy in the overall effort to facilitate healthcare price transparency in the United States.

Evaluating the HHS report on the No Surprises Act

Turquoise Health's review of the first HHS annual report on the No Surprises Act analyzing stalled or broken processes within the NSA and providing recommended pathways forward for payers and regulators. Read our full analysis.

2023 price transparency impact report

Turquoise 2023 price transparency impact report dives into payer data quality and utility, innovation in upfront patient estimates, and recommended steps for improving price transparency data and compliance across the industry. Explore the data.

2022 price transparency impact report

Turquoise Health's inaugural price transparency impact report covering the state of hospital and payer compliance, third-party innovation, and the government actions needed for price transparency to fully integrate into US healthcare. Explore the data.